<DOC>
	<DOC>NCT01228747</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged â‰¥16 years and with uncontrolled Generalized Tonic-Clonic seizures despite treatment with 1 or 2 anti-epileptic drugs.</brief_summary>
	<brief_title>A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>An epilepsy patient with generalized tonicclonic seizures that are classifiable according to the ILAE classification of epileptic seizures (Epilepsia, 1981) A patient on a stable dose of 1 or 2 antiepileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to and during the combined baseline period Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures Diagnosis of LennoxGastaut Syndrome Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imagining features A history of convulsive or nonconvulsive status epilepticus while taking concomitant antiepileptic drugs for the last 3 months prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>epilepsy</keyword>
	<keyword>generalized tonic-clonic</keyword>
</DOC>